标题
Dilemma of first line regimens in metastatic pancreatic adenocarcinoma
作者
关键词
-
出版物
WORLD JOURNAL OF GASTROENTEROLOGY
Volume 22, Issue 46, Pages 10124
出版商
Baishideng Publishing Group Inc.
发表日期
2016-12-13
DOI
10.3748/wjg.v22.i46.10124
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- nab-Paclitaxel Plus Gemcitabine Versus Gemcitabine in Patients with Metastatic Pancreatic Adenocarcinoma: Canadian Subgroup Analysis of the Phase 3 MPACT Trial
- (2016) Mustapha Tehfe et al. ADVANCES IN THERAPY
- Second-line therapy after nab-paclitaxel plus gemcitabine or after gemcitabine for patients with metastatic pancreatic cancer
- (2016) E Gabriela Chiorean et al. BRITISH JOURNAL OF CANCER
- Final analysis of a phase II study of modified FOLFIRINOX in locally advanced and metastatic pancreatic cancer
- (2016) Stacey M Stein et al. BRITISH JOURNAL OF CANCER
- Cancer statistics, 2016
- (2016) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Metastatic Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline
- (2016) Davendra P.S. Sohal et al. JOURNAL OF CLINICAL ONCOLOGY
- Cost description of chemotherapy regimens for the treatment of metastatic pancreas cancer
- (2016) Daniel A. Goldstein et al. MEDICAL ONCOLOGY
- Image-based detection and targeting of therapy resistance in pancreatic adenocarcinoma
- (2016) Raymond G. Fox et al. NATURE
- Is metastatic pancreatic cancer an untargetable malignancy?
- (2016) Hampig Raphael Kourie et al. World Journal of Gastrointestinal Oncology
- Cancer of the pancreas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- (2015) M. Ducreux et al. ANNALS OF ONCOLOGY
- A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS)
- (2015) N. I. Cherny et al. ANNALS OF ONCOLOGY
- Nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after Folfirinox failure: an AGEO prospective multicentre cohort
- (2015) Alix Portal et al. BRITISH JOURNAL OF CANCER
- Economic evaluation for the UK of nab-paclitaxel plus gemcitabine in the treatment of metastatic pancreas cancer
- (2015) M Gharaibeh et al. BRITISH JOURNAL OF CANCER
- nab-Paclitaxel Plus Gemcitabine for Metastatic Pancreatic Cancer: Long-Term Survival From a Phase III Trial
- (2015) D. Goldstein et al. JNCI-Journal of the National Cancer Institute
- Safety and Efficacy of Modified FOLFIRINOX for Advanced Pancreatic Adenocarcinoma: A UK Single-Centre Experience
- (2015) Ehsan Ghorani et al. ONCOLOGY
- nab-Paclitaxel Plus Gemcitabine for Metastatic Pancreatic Cancer: Long-Term Survival From a Phase III Trial
- (2015) D. Goldstein et al. JNCI-Journal of the National Cancer Institute
- Stromal Elements Act to Restrain, Rather Than Support, Pancreatic Ductal Adenocarcinoma
- (2014) Andrew D. Rhim et al. CANCER CELL
- 5-Fluorouracil/Leucovorin Combined with Irinotecan and Oxaliplatin (FOLFIRINOX) as Second-Line Chemotherapy in Patients with Advanced Pancreatic Cancer Who Have Progressed on Gemcitabine-Based Therapy
- (2014) Min Geun Lee et al. CHEMOTHERAPY
- Cost-effectiveness of FOLFIRINOX for first-line treatment of metastatic pancreatic cancer
- (2014) C.L. Attard et al. Current Oncology
- A Bayesian Meta-Analysis of Multiple Treatment Comparisons of Systemic Regimens for Advanced Pancreatic Cancer
- (2014) Kelvin Chan et al. PLoS One
- Economic Evaluation of NAB-Paclitaxel Plus Gemcitabine Versus Gemcitabine Alone for The Management of Metastatic Pancreatic Cancer in Greece
- (2014) V. Fragoulakis et al. VALUE IN HEALTH
- Quality-adjusted survival with combination nab-paclitaxel + gemcitabine vs gemcitabine alone in metastatic pancreatic cancer: a Q-TWiST analysis
- (2014) Michele Reni et al. JOURNAL OF MEDICAL ECONOMICS
- Do hENT1 and RRM1 predict the clinical benefit of gemcitabine in pancreatic cancer?
- (2013) Lars Petter Jordheim et al. Biomarkers in Medicine
- Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
- (2013) Daniel D. Von Hoff et al. NEW ENGLAND JOURNAL OF MEDICINE
- Probability of Cancer in Pulmonary Nodules Detected on First Screening CT
- (2013) Annette McWilliams et al. NEW ENGLAND JOURNAL OF MEDICINE
- Modified FOLFIRINOX Regimen With Improved Safety and Maintained Efficacy in Pancreatic Adenocarcinoma
- (2013) Hemchandra Mahaseth et al. PANCREAS
- Impact of FOLFIRINOX Compared With Gemcitabine on Quality of Life in Patients With Metastatic Pancreatic Cancer: Results From the PRODIGE 4/ACCORD 11 Randomized Trial
- (2012) Sophie Gourgou-Bourgade et al. JOURNAL OF CLINICAL ONCOLOGY
- A multicenter analysis of GTX chemotherapy in patients with locally advanced and metastatic pancreatic adenocarcinoma
- (2011) Ana De Jesus-Acosta et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Gemcitabine Plusnab-Paclitaxel Is an Active Regimen in Patients With Advanced Pancreatic Cancer: A Phase I/II Trial
- (2011) Daniel D. Von Hoff et al. JOURNAL OF CLINICAL ONCOLOGY
- FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
- (2011) Thierry Conroy et al. NEW ENGLAND JOURNAL OF MEDICINE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreDiscover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversation